RxDoctor Payments Data

Mersedeh Karimian, DO

Pain Medicine · Apple Valley, CANPI 1952516304

Payments from drug & device makers

$11,686in general payments, 2019–2025

Across 200 payments — averaging $58.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$9K
  • Boston Scientific$769
  • Biotronik NRO, Inc.$539
  • AbbVie$382
  • SPR Therapeutics, Inc$135
  • Medtronic$104
  • plus $422 from 9 others

What the payments were for

  • Travel & lodging$4,15136%
  • Food & beverage$7,53464%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott147$9,335
Boston Scientific16$769
Biotronik NRO, Inc.10$539
AbbVie(2 entities)7$382
SPR Therapeutics, Inc1$135
Medtronic5$104
Novo Nordisk1$99
Si-bone, Inc.1$88
Laborie Medical Technologies Corp.2$73
Nalu Medical, Inc.5$60
Axonics, Inc.1$33
Vertos Medical, Inc.1$19
Vertiflex, Inc.1$19
Venclose Inc.1$18
Virtus Pharmaceuticals LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,686 in reported general payments places this provider in the 80th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California

Medicare billing

Part B allowed, 2024
$180,511
Medicare patients
181
Services billed
2,934

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl28$22,210
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen822$21,983
NucyntaTapentadol Hcl11$19,940
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen405$17,333
Fentanyl112$14,159
LinzessLinaclotide26$13,898
Pregabalin133$5,887
Oxycodone Hcl180$5,544
Morphine Sulfate ErMorphine Sulfate192$5,475
Lidocaine42$5,106
Gabapentin165$2,037
Tizanidine Hcl198$1,700
Morphine Sulfate40$1,589
Hydromorphone Hcl75$1,588
Carisoprodol84$1,264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$382$13,89826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 840 pain medicine providers in California.

Other pain medicine in Apple Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →